OTCMKTS:ENDV

Endonovo Therapeutics (ENDV) Stock Forecast, Price & News

$0.01

0.00 (-0.67%)

(As of 01:00 PM ET)

Compare

Today's Range: $0.0148
▼
$0.0149
50-Day Range: $0.01
▼
$0.0199
52-Week Range: $0.00
▼
$0.03

Volume: 13,784 shs
Average Volume: 353,251 shs
Market Capitalization: $4.09 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Earnings Financials Insider Trades Headlines SEC Filings Short Interest

About Endonovo Therapeutics (OTCMKTS:ENDV) Stock

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development, manufacture, and distribution of medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, and SofPulse Electroceutical Therapy. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

Receive ENDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENDV Stock News Headlines

May 2, 2023 | finance.yahoo.com

Endonovo Launches SofPulse® into the Veterans Administration

April 27, 2023 | americanbankingnews.com

Endonovo Therapeutics (OTCMKTS:ENDV) Stock Price Crosses Below 50 Day Moving Average of $0.02

May 31, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

April 25, 2023 | finance.yahoo.com

Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies

April 13, 2023 | finance.yahoo.com

Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman

April 10, 2023 | finance.yahoo.com

Endonovo Announces Partnership with Santana Lead Singer Andy Vargas

March 29, 2023 | finance.yahoo.com

Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company

March 23, 2023 | finance.yahoo.com

Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan

May 31, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

March 15, 2023 | finance.yahoo.com

Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery

March 9, 2023 | finance.yahoo.com

Endonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy Medical

March 6, 2023 | finance.yahoo.com

Endonovo Announces Distribution Agreement with Academy Medical

February 28, 2023 | finance.yahoo.com

Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg

January 31, 2023 | finance.yahoo.com

Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off

January 26, 2023 | finance.yahoo.com

Endonovo Partners with International Distributor for SofPulse® Line

January 23, 2023 | reuters.com

ENDV.PK - | Stock Price & Latest News | Reuters

January 19, 2023 | finance.yahoo.com

New Details on Endonovo’s Spin-Off of SofPulse, Inc.

January 9, 2023 | finance.yahoo.com

Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as a Listed Public Company

January 3, 2023 | finance.yahoo.com

Endonovo Targets Dept. of Defense, VA & Federal Contracts

December 19, 2022 | finance.yahoo.com

Endonovo Announces Advancement of International “Go to Market” Initiative

December 15, 2022 | finance.yahoo.com

Endonovo Announces Plans for Spin-off of Medical IP and Assets

December 13, 2022 | finance.yahoo.com

Endonovo Launches Telehealth Initiative

November 22, 2022 | markets.businessinsider.com

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Third Quarter 2022 Financial Results and Highlights Operational Progress

November 17, 2022 | finance.yahoo.com

ENDONOVO ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES FOR ITS SOFPULSE® MEDICAL DEVICE ASSETS

November 7, 2022 | finance.yahoo.com

Endonovo Therapeutics Issues Corporate Update

November 3, 2022 | msn.com

Acrivon Therapeutics sets IPO price range

September 30, 2022 | markets.businessinsider.com

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ENDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endonovo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENDV Company Calendar

Today: 5/31/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Electromedical equipment
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ENDV
CUSIP: N/A
CIK: 1528172
Web: www.endonovo.com
Phone: (800) 489-4774
Fax: 818-230-9899
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,480,000.00
Net Margins: -3,988.29%
Pretax Margin: -3,988.29%
Return on Equity: N/A
Return on Assets: -639.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $140,000.00
Price / Sales: 29.37
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.09) per share
Price / Book: -0.17

Miscellaneous

Outstanding Shares: 276,290,000
Free Float: 260,785,000
Market Cap: $4.11 million
Optionable: Not Optionable
Beta: 0.25

Key Executives

Alan Brian Collier
Chairman, CEO, CFO & Secretary

Don Calabria
Vice President-Operations

Garry Michael Kann
Head-Corporate Development

Ira Weisberg
President-Medical Division

David Clark
Vice President-Sales

Key Competitors

View All Competitors

ENDV Stock - Frequently Asked Questions

How have ENDV shares performed in 2023?: Endonovo Therapeutics' stock was trading at $0.0180 at the beginning of the year. Since then, ENDV shares have decreased by 17.3% and is now trading at $0.0149.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Endonovo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Endonovo Therapeutics investors own include Chesapeake Energy (CHKAQ), Energous (WATT), Advanced Micro Devices (AMD), BioLineRx (BLRX), Ekso Bionics (EKSO), Geron (GERN), Marinus Pharmaceuticals (MRNS), Micron Technology (MU), Novavax (NVAX) and Exxon Mobil (XOM).
What is Endonovo Therapeutics' stock symbol?: Endonovo Therapeutics trades on the OTCMKTS under the ticker symbol "ENDV."

How do I buy shares of Endonovo Therapeutics?: Shares of ENDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Endonovo Therapeutics' stock price today?: One share of ENDV stock can currently be purchased for approximately $0.01.
How much money does Endonovo Therapeutics make?: Endonovo Therapeutics (OTCMKTS:ENDV) has a market capitalization of $4.11 million and generates $140,000.00 in revenue each year.
How can I contact Endonovo Therapeutics?: Endonovo Therapeutics' mailing address is 6320 CANOGA AVENUE 15TH FLOOR, WOODLAND HILLS CA, 91367. The official website for the company is www.endonovo.com. The biotechnology company can be reached via phone at (800) 489-4774, via email at sbarnes@endonovo.com, or via fax at 818-230-9899.

This page (OTCMKTS:ENDV) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial